» Articles » PMID: 25420283

Hypersensitivity Reactions to Intravenous Iron: Guidance for Risk Minimization and Management

Overview
Journal Haematologica
Specialty Hematology
Date 2014 Nov 25
PMID 25420283
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare but can be life-threatening. This paper reviews their frequency, pathogenesis and risk factors, and provides recommendations about their management and prevention. Complement activation-related pseudo-allergy triggered by iron nanoparticles is probably a more frequent pathogenetic mechanism in acute reactions to current formulations of intravenous iron than is an immunological IgE-mediated response. Major risk factors for hypersensitivity reactions include a previous reaction to an iron infusion, a fast iron infusion rate, multiple drug allergies, severe atopy, and possibly systemic inflammatory diseases. Early pregnancy is a contraindication to iron infusions, while old age and serious co-morbidity may worsen the impact of acute reactions if they occur. Management of iron infusions requires meticulous observation, and, in the event of an adverse reaction, prompt recognition and severity-related interventions by well-trained medical and nursing staff.

Citing Articles

The experiences of ferric carboxymaltose desensitization and provocation.

Dindar Celik F, Aksu K, Akkale O, Celik Tuglu H, Yagdiran M, Telli O World Allergy Organ J. 2025; 18(2):101025.

PMID: 39902113 PMC: 11787419. DOI: 10.1016/j.waojou.2024.101025.


Personalized Risk Assessment for Taxane-Induced Hypersensitivity Reactions: A Systematic Review and Meta-Analysis.

Park H, Ko M, Kim I, Oh J J Pers Med. 2025; 15(1.

PMID: 39852195 PMC: 11767215. DOI: 10.3390/jpm15010002.


Cost-effectiveness of ferric citrate hydrate in patients with iron deficiency anemia.

Momoeda M, Ito K, Inoue S, Shibahara H, Mitobe Y, Komatsu N Int J Hematol. 2024; .

PMID: 39724235 DOI: 10.1007/s12185-024-03905-x.


Iron Treatment in Patients with Iron Deficiency Before and After Metabolic and Bariatric Surgery: A Narrative Review.

Kaberi-Otarod J, Still C, Wood G, Benotti P Nutrients. 2024; 16(19).

PMID: 39408317 PMC: 11478352. DOI: 10.3390/nu16193350.


Nanoparticle-Binding Immunoglobulins Predict Variable Complement Responses in Healthy and Diseased Cohorts.

Li Y, Saba L, Scheinman R, Banda N, Holers M, Monte A ACS Nano. 2024; 18(42):28649-28658.

PMID: 39395006 PMC: 11651220. DOI: 10.1021/acsnano.4c05087.


References
1.
Edwards A, Elwyn G, Mulley A . Explaining risks: turning numerical data into meaningful pictures. BMJ. 2002; 324(7341):827-30. PMC: 1122766. DOI: 10.1136/bmj.324.7341.827. View

2.
Jahn M, Andreasen H, Futterer S, Nawroth T, Schunemann V, Kolb U . A comparative study of the physicochemical properties of iron isomaltoside 1000 (Monofer), a new intravenous iron preparation and its clinical implications. Eur J Pharm Biopharm. 2011; 78(3):480-91. DOI: 10.1016/j.ejpb.2011.03.016. View

3.
Chertow G, Winkelmayer W . On the relative safety of intravenous iron formulations: new answers, new questions. Am J Hematol. 2010; 85(9):643-4. DOI: 10.1002/ajh.21835. View

4.
Ring J, Grosber M, Mohrenschlager M, Brockow K . Anaphylaxis: acute treatment and management. Chem Immunol Allergy. 2010; 95:201-210. DOI: 10.1159/000315953. View

5.
Szebeni J, Baranyi L, Savay S, Bodo M, Milosevits J, Alving C . Complement activation-related cardiac anaphylaxis in pigs: role of C5a anaphylatoxin and adenosine in liposome-induced abnormalities in ECG and heart function. Am J Physiol Heart Circ Physiol. 2005; 290(3):H1050-8. DOI: 10.1152/ajpheart.00622.2005. View